3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
132
Myelodysplastic Syndromes
57
Leukemia
32
Leukemia, Myelomonocytic, Chronic
23
Recurrence
18
Lymphoma, Large B-Cell, Diffuse
10
Myeloproliferative Disorders
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Neoplasms
8
Congenital Abnormalities
7
Primary Myelofibrosis
6
Melanoma
6
Hodgkin Disease
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Ovarian Neoplasms
5
Blast Crisis
5
Thrombocythemia, Essential
4
Polycythemia Vera
4
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma
4
Leukemia, Monocytic, Acute
4
Leukemia, Biphenotypic, Acute
4
Anemia, Refractory, with Excess of Blasts
4
Neoplasm Metastasis
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Myeloid, Accelerated Phase
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Interventions
Specimen Handling
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Congenital Bone Marrow Failure Syndromes
×
Decitabine
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled